TREACE MEDICAL CONCEPTS, INC. (TMCI) News
Filter TMCI News Items
TMCI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TMCI News Highlights
- TMCI's 30 day story count now stands at 8.
- Over the past 15 days, the trend for TMCI's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about TMCI are ROSE.
Latest TMCI News From Around the Web
Below are the latest news stories about TREACE MEDICAL CONCEPTS INC that investors may wish to consider to help them evaluate TMCI as an investment opportunity.
'Dodged a bullet': How fall of SVB is affecting First Coast companiesAs Jacksonville tries to grow its startup sector, here's how some are reacting in the wake of the collapse of Silicon Valley Bank. |
Why Treace Medical Concepts' Shares Rose WednesdayShares of Treace Medical Concepts (NASDAQ: TMCI) were up 21% as of 3 p.m. EST Wednesday afternoon. The orthopedic medical device company's shares rose after it reported fourth-quarter earnings after the markets closed on Tuesday. Treace makes Lapiplasty surgery kits, which orthopedic surgeons use to perform minimally invasive surgery on bunions. |
Q4 2022 Treace Medical Concepts Inc Earnings CallQ4 2022 Treace Medical Concepts Inc Earnings Call |
Ponte Vedra-based Treace posts $4.4M loss for Q4, beating analysts expectationsOrthopedic medical device company Treace Medical Concepts Inc. reported a loss of $4.4 million in the fourth quarter despite revenues increasing quarter over quarter and year over year. Revenue for Q4 was $49.8 million, representing an increase of 49% compared to $33.4 million in the year-ago quarter. The increase was driven by a growing number of surgeons buying the company's Lapiplasty procedure kits — which are used to treat bunions — and higher prices due to newer technologies and an expanded product line, the company said. |
Treace Medical Concepts Reports Fourth Quarter and Full Year 2022 Financial ResultsPONTE VEDRA, Fla., March 07, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights: Revenue of $49.8 million in the fourth quarter of 2022, a 49% increase over the same period last year and a 51% increase sequen |
Treace Medical Announces Settlement of Lawsuit Again Fusion OrthopedicsPONTE VEDRA, Fla., March 03, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) jointly announces with Fusion Orthopedics, LLC (“Fusion Orthopedics”) that they have reached an amicable resolution of the litigation between the parties. Treace Medical filed the lawsuit on March 29, 2022 against Fusion Orthopedics i |
Treace Medical Announces Settlement of Lawsuit Against Fusion OrthopedicsPONTE VEDRA, Fla., March 03, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) jointly announces with Fusion Orthopedics, LLC (“Fusion Orthopedics”) that they have reached an amicable resolution of the litigation between the parties. Treace Medical filed the lawsuit on March 29, 2022 against Fusion Orthopedics i |
Treace to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023PONTE VEDRA, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Tuesday, March 7, 2023. Company management will host a conference call to |
Treace Presents Updated ALIGN3D™ Interim Data and Latest Product Innovations at the 2023 ACFAS Annual ConferencePONTE VEDRA, Fla., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure today announced it will highlight new interim clinical data from the ALIGN3D™ study, and recent product innovations, at the 2023 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Con |
Treace Medical Concepts, Inc. Announces Pricing of $100.0 Million Public Offering of Common StockPONTE VEDRA, Fla., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced the pricing of an underwritten public offering of 4,761,905 shares of its common stock at a public offering price of $21.00 per share, before underwriting discounts and commissions. All o |